Evidence Level
Chondroitin sulfate is a well-supported treatment for knee osteoarthritis (OA), as evidenced by multiple studies. Kahan et al. (2009) conducted a two-year, randomized, double-blind, placebo-controlled trial and found that chondroitin sulfate provided both symptom relief and structural benefits in patients with knee OA. In a comparative study, Reginster et al. (2017) demonstrated that pharmaceutical-grade chondroitin sulfate was non-inferior to celecoxib for pain relief in symptomatic knee OA.
The variability in product quality has been identified as a key factor influencing the outcomes of trials. Regulated European manufacturers have produced superior results compared to unregulated over-the-counter products, highlighting the importance of using high-quality, pharmaceutical-grade chondroitin sulfate (Kahan et al., 2009; Reginster et al., 2017). The 2018 ESCEO guidelines recommend pharmaceutical-grade chondroitin sulfate as a first-line treatment for knee OA.
Clegg et al. (2006) confirmed the additive benefit of combining glucosamine and chondroitin in moderate-to-severe cases, while recent studies like Wang et al. (2022) and Meng et al. (2023) support their combined use for improved WOMAC scores. However, Rabade et al. (2024) found no significant benefits from the combination beyond individual components. Knapik et al. (2019) highlighted that higher doses (1200mg/d) are more effective in reducing pain, though structural effects remain minimal.
While Ruiz-Romero et al. (2025) found modest improvements in temporomandibular dysfunction with chondroitin-glucosamine, no significant pain reduction compared to tramadol was observed. Overall, chondroitin sulfate remains a valuable treatment option for knee osteoarthritis when used as a high-quality, regulated product.